2 weeks Ago By Defense World Staff
Geode Capital Management LLC trimmed its holdings in Embecta Corp. (NASDAQ:EMBC – Free Report) by 0.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The institutional investor owned 1,383,834 shares of the company’s stock after selling 3,439 shares during the period. Geode Capital Management LLC owned about 2.38% of Embecta worth $28,583,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Garden State Investment Advisory Services LLC bought a new position in Embecta in the 3rd quarter valued at about $438,000. Barclays PLC raised its stake in shares of Embecta by 41.
1% in the third quarter. Barclays PLC now owns 97,930 shares of the company’s stock worth $1,381,000 after purchasing an additional 28,523 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Embecta by 156.
1% in the third quarter. Jane Street Group LLC now owns 176,487 shares of the company’s stock valued at $2,488,000 after purchasing an additional 107,567 shares in the last quarter. Oppenheimer Asset Management Inc.
purchased a new position in shares of Embecta during the fourth quarter valued at approximately $209,000. Finally, Bank of New York Mellon Corp grew its holdings in Embecta by 0.7% during the fourth quarter.
Bank of New York Mellon Corp now owns 685,493 shares of the company’s stock worth $14,155,000 after buying an additional 4,769 shares in the last quarter. 93.83% of the stock is currently owned by institutional investors and hedge funds.
Embecta Price PerformanceEMBC stock opened at $11.34 on Friday. The firm has a market cap of $659.
24 million, a PE ratio of 11.34, a P/E/G ratio of 0.78 and a beta of 1.
23. The business has a 50 day moving average of $13.24 and a 200-day moving average of $15.
90. Embecta Corp. has a 12-month low of $10.
00 and a 12-month high of $21.48. Embecta (NASDAQ:EMBC – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th.
The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.
20. Embecta had a negative return on equity of 19.22% and a net margin of 5.
25%. On average, research analysts expect that Embecta Corp. will post 2.
85 earnings per share for the current year. Embecta Announces DividendThe business also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were paid a $0.
15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 5.
29%. The ex-dividend date was Friday, February 28th. Embecta’s payout ratio is 60.
00%. Wall Street Analyst Weigh InSeparately, Mizuho assumed coverage on Embecta in a research note on Thursday, April 10th. They set a “neutral” rating and a $15.
00 price objective on the stock.Check Out Our Latest Stock Report on EMBCInsider ActivityIn other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $16.
38, for a total transaction of $50,778.00. Following the completion of the transaction, the director now directly owns 36,133 shares of the company’s stock, valued at approximately $591,858.
54. This represents a 7.90 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.42% of the company’s stock.
About Embecta (Free Report)Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Featured StoriesFive stocks we like better than EmbectaWhat is MarketRankTM? How to Use itTariff Exemptions Set the Stage for a Taiwan Semiconductor RallyTop Biotech Stocks: Exploring Innovation OpportunitiesMitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. DollarInvesting in Construction StocksBroadcom’s Apple Relationship: AI Opportunity Meets Tariff RiskWant to see what other hedge funds are holding EMBC? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC – Free Report)..
